Abstract
A systematic review including 118 clinical trials found that only acamprosate and oral naltrexone (50 mg/day, the standard dose recommended by the U.S. Food and Drug Administration) were effective for alcohol use disorder (AUD) using the following measures.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
